0 of 7 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading...
You must sign in or sign up to start the quiz.
You have to finish following quiz, to start this quiz:
Currently, how confident are you in your ability to:
1 = not confident, 2 = somewhat confident, 3 = confident, 4 = very confident, 5 = extremely confident, N/A = not applicable to me
Recognize the role of biomarkers in disease progression and response to therapy in MS
Apply recent data regarding imaging guidelines and best practices in clinic
Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with multiple sclerosis.
*1 = Never, 2 = Not often, 3 = Sometimes, 4 = Often, 5 = Always, N/A = Not applicable to me
Understand the mechanism of action of approved therapies in the multiple sclerosis treatment landscape
Consider recent data, including that of combination therapy, when making therapeutic decisions for MS patients and providing personalized patient care
1. The role of serum neurofilament light (sNfL) as a biomarker in MS was studied in 750 patients enrolled in phase III clinical trials. The results of the study revealed that sNfL levels were associated concurrently with all of the following, except:
2. Generally, patients with recurrent optic neuritis (rON), meaning they have had 2+ attacks, are:
3. An analysis of the value of neurofilament light as a biomarker of response to ocrelizumab in patients with relapsing and primary progressive multiple sclerosis showed that at 12 and 24 weeks post-treatment, all of the following were reduced, except:
4. The mechanism of action of which of the below agents was shown to cause a depletion of memory T-cells, Th1 cells and memory B-cells?
5. A recent study of spinal cord magnetic resonance imaging (SC-MRI) measures in 75 relapsing and progressive MS patients indicated a correlation between patients with worsening disability and decreasing SC-CSA. To make this determination, patients were measured at: